Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-Week results

AIDS

Volumn 17, Issue 18, 2003, Pages 2603-2614

  Murphy, Robert L ^a,f   Sanne, Ian ^b   Cahn, Pedro ^c   Phanuphak, Praphan ^d   Percival, Lisa ^e   Kelleher, Thomas ^e   Giordano, Michael ^e  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WHC Infect Dis Clin Trials Unit   (South Africa)

^c FUNDACIÓN HUÉSPED   (Argentina)

^d CHULALONGKORN UNIVERSITY   (Thailand)

^e BRISTOL MYERS SQUIBB   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Atazanavir; Cardiovascular disease; Highly active antiretroviral therapy; Hyperlipidemia; Protease inhibitors

Indexed keywords

ATAZANAVIR; CD4 ANTIGEN; DIDANOSINE; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; INFECTION; JAUNDICE; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; LIPODYSTROPHY; LIVER TOXICITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PHASE 2 CLINICAL TRIAL; PILL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SINGLE BLIND PROCEDURE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ACIDOSIS, LACTIC; ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL, LDL; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NELFINAVIR; OLIGOPEPTIDES; PYRIDINES; RNA, VIRAL; STAVUDINE; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 1642465026     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200312050-00007     Document Type: Article

References (54)

1. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-733.
2. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA 1998, 279:930-937.
3. Moyle GJ, Baldwin C. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy [letter]. J Acquir Immune Defic Syndr 1999, 21:423-424.
4. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51-57.
5. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000, 23:35-43.
6. Ho TTY, Chan KCW, Wong KH, Lee SS. Abnormal fat distribution and use of protease inhibitors. Lancet 1998, 351: 1736-1737.
7. Martinez E, Mocroft A, García-Viejo MA, Pérez-Cuevas JB, Blanco JL, Mallolas J, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001, 357:592-598.
8. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000, 160:2050-2056.
9. Dubé MP, Sprecher D, Henry WK, Aberg JA, Torriani FJ, Hodis HN, et al. for the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adult AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin Infect Dis 2000, 31:1216-1224.
10. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
11. Gong Y-F, Robinson B, Rose R, Deminie C, Spicer T, Markowitz M, et al. Antiviral activity and resistance profile of an HIV-1 protease inhibitor BMS-232632. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, September 1998 [abstract I-79].
12. Rabasseda X, Silvestre J, Castañer J. BMS-232632. Drugs of the Future 1999, 24:375-380.
13. O'Mara EM, Smith J, Olsen SJ, Tanner T, Schuster AE, Kaul S. BMS-232632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers. Sixth Conference on Retroviruses and Opportunistic Infections. Chicago, January-February 1999 [abstract 604].
14. Squires K, Gatell J, Piliero P, Sanne I, Wood R, Schnittman SM. AI424-007: 48-week safety and efficacy results from a phase II study of a once-daily HIV-1 protease inhibitor (PI), BMS-232632. Eighth Conference on Retroviruses and Opportunistic Infections. Chicago, February 2001 [abstract 15].
15. Sanne I, Piliero P, Wood R, Kelleher T, Cross A, Mongillo A, et al. Safety and antiviral efficacy of a novel once-daily HIV-1 protease inhibitor BMS-232632: preliminary results from a phase II clinical trial. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January-February 2000 [abstract 672].
16. O'Mara E, Mummaneni V, Randall D, Sagali N, Olsen S, Tanner T, et al. BMS-232632: a summary of multiple dose pharmacokinetic, food effect and drug interaction studies in healthy subjects. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January-February 2000.
17. Piliero P. The utility of inhibitory quotients in determining relative potency of protease inhibitors. AIDS 2002, 16:799-800.
18. Gong Y-F, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000, 44:2319-2326.
19. Colonno RJ, Friborg J, Rose RE, Lam E, Parkin N. Identification of amino acid substitutions correlated with reduced atazanavir susceptibility in patients treated with atazanavir containing regimens [abstract 4]. Antivir Ther 2002, 7(suppl 1):S6.
20. Haas DW, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48). Ninth Conference for Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 42].
21. Piliero PJ, Cahn P, Pantaleo G, Gatell J, Squires K, Percival L, et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile - results of clinical trials beyond week 48. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 706-T].
22. Sanne I, Cahn P, Percival L, Phanuphak P, Kelleher TGM, Pantaleo C. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV(+) patients (AI424-008). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, December 2001 [abstract I-667].
23. Diggle PJ, Liang K-Y, Zeger SL. Analysis of Longitudinal Data. New York: Oxford University Press; 1994.
24. Fleiss JL. Statistical Methods for Rates and Proportions. New York: John Wiley & Sons; 1981.
25. Braunwald E, Hauser SL, Fauci AS, Kasper DL, Longo DL, Jameson JL, et al. (eds) Harrison's Principles of Internal Medicine. New York: McGraw-Hill; 2001.
26. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, et al. (eds) Pharmacotherapy. A Pathophysiologic Approach. Stamford: Appleton & Lange; 1999.
27. Düsing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001, 3:488-492.
28. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984, 6:592-599.
29. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000, 133: 21-30.
30. Eldred LJ, Wu AW, Chaisson RE, Moore RD. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr 1998, 18:117-125.
31. Pratt DS, Kaplan MM. Evaluation of liver function. In Harrison's Principles of Internal Medicine. Edited by Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL. New York: McGraw-Hill; 2002:1711-1715.
32. Kaplan M, Hammerman C, Rubaltelli FF, Vilei MT, Levy-Lahad E, Renbaum P, et al. Hemolysis and bilirubin conjugation in association with UDP-glucuronosyltransferase 1A1 promoter polymorphism. Hepatology 2002, 35:905-911.
33. Zucker S, Qin X, Rouster S, Yu F, Green R, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001, 98:12671-12676.
34. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis 2002, 15:23-29.
35. Gervasoni C, Ridolfo AL, Trifirò G, Santambrogio S, Norbiato G, Musicco M, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 1999, 13:465-471.
36. Benson JO, McGhee K, Coplan P, Grunfeld C, Robertson M, Brodovicz KG, et al. Fat redistribution in indinavir-treated patients with HIV infection: A review of postmarketing cases. J Acquir Immune Defic Syndr 2000, 25:130-139.
37. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-F58.
38. Berger A. Protease inhibitors may cause fat abnormalities and heart disease. BMJ 1998, 317:100.
39. Penzak SR, Chuck SK. Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scand J Infect Dis 2000, 32:111-123.
40. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351: 1881-1883.
41. Riddler S, Smit E, Li R, Cole S, Chmiel J, Dobs A, et al. Serum lipids and antiretroviral therapy among HIV-infected men. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 750].
42. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001, 104:257-262.
43. Clumeck N. Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy. Antivir Ther 1998, 3(suppl 4):39-43.
44. Lennernäs H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997, 32:403-425.
45. Hsyu P, Lewis R, Schultz M, Lillibridge J, Kerr B. Pharmacokinetic interactions between nelfinavir and two HMC-CoA reductase inhibitors simvastatin and atorvastatin. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, September 2000 [abstract 425].
46. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000, 38:41-57.
47. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999, 246:567-575.
48. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Körner T, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13:F63-F70.
49. Rockstroh JK, Bergmann F, Wiesel W, Rieke A, Thiesen A, Fätkenheuer G, et al. for the German Ritonavir/Indinavir Study Group. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. AIDS 2000, 14:1181-1185.
50. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. for the European-Australian Collaborative Ritonavir Study Group. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995, 333:1528-1533.
51. Pernerstorfer-Schoen H, Jilma B, Perschler A, Wichlas S, Schindler K, Schindl A, et al. Sex differences in HAART-associated dyslipidaemia. AIDS 2001, 15:725-734.
52. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients. Clin Infect Dis 1999, 29:441-443.
53. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis 2000, 30(suppl 2):S171-S176.
54. Gatanaga H, Aizawa S, Kikuchi Y, Tachikawa N, Genka I, Yoshizawa S, et al. Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors. AIDS Res Hum Retroviruses 1999, 15:1493-1498.